Continuous Chromatography & PAT in Modern Biomanufacturing

As upstream titers consistently surpass 5–8 g/L across mammalian biomanufacturing platforms, conventional batch downstream purification faces significant bottleneck constraints. Facility footprint limitations, high Protein A resin replacement costs, and substantial buffer consumption have accelerated the adoption of continuous chromatography and Process Analytical Technology (PAT) within Canada's growing biomanufacturing sector.

Multi-Column Countercurrent Chromatography (MCC)

Multi-Column Chromatography (MCC)—operating under Periodic Counter-Current (PCC) or simulated moving bed principles—connects multiple smaller columns in series. While the primary column is overloaded past standard dynamic binding capacity (DBC) breakthrough (often achieving 80–90% resin saturation), the breakthrough fraction is captured on the subsequent secondary column. This setup increases resin capacity utilization by over 40%, slashes overall resin volume requirements, and eliminates non-productive downtime between batch cycling.

Real-Time Quality Control through PAT

Implementing continuous purification requires robust real-time monitoring rather than offline quality control testing. Advanced inline multi-wavelength UV/Vis spectrometers, refractive index detectors, and rapid capacitance sensors continuously track protein concentration, aggregate levels, and buffer conductivities. When integrated into SCADA/DeltaV control loops, PAT enables automated column switching, dynamic diversion of off-spec fractions, and tight adherence to Critical Quality Attributes (CQAs), aligning fully with Health Canada and FDA ICH Q13 guidelines on continuous manufacturing.